Since that analysis recruited participants from a single neuro-ophthalmology practice (Massachusetts Eye and Ear in Boston), a separate team of researchers questioned whether these findings apply to broader populations
Most strikingly, multiple trials have now shown that GLP-1 agonists can lead to the resolution of MASH, a severe form of fatty liver disease, without worsening of liver fibrosis, which is a common adverse outcome seen with some current medications
Inflammatory cytokine suppression: In bile duct-ligated rats, BPC-157 therapy reduced NOS3 expression and lowered IL-6, TNF-alpha, and IL-1-beta levels in liver tissue three key inflammatory drivers of liver damage [4]
Do NOT use it if safety seal is damaged or missing
Injections work faster, while supplements take longer but are more convenient and affordable
Results are noticeable after the second round of treatment